ArticleFrontiers in immunology2026
A-to-I RNA editing profiles and distinct immune responses in myelin oligodendrocyte glycoprotein antibody-positive optic neuritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis (MOG-ON) is an autoimmune inflammatory demyelinating disorder of the optic nerve that often results in severe visual impairment and recurrent attacks. Although immune dysregulation is recognized as a central feature of MOG-ON, the contribution of post-transcriptional regulatory mechanisms, particularly adenosine-to-inosine (A-to-I) RNA editing, to disease pathogenesis and visual outcomes remains poorly understood. In this study, we characterized A-to-I RNA editing in MOG-ON, investigated molecular signatures and immune responses across the acute and remission phases, and explored candidate genes and associations with visual outcomes. Methods: A total of 14 peripheral blood samples were collected from patients with MOG-ON (9 in the acute phase and 5 in remission) and from 7 healthy controls. The A-to-I editome was characterized using RNA editing profiling, and stage-associated molecular signatures and immune responses were investigated using transcriptomic sequencing. In addition, functional enrichment analysis, immune pathway profiling, and estimated immune-cell proportions analysis were performed. Results: MOG-ON exhibited extensive A-to-I RNA editing remodeling, with 240 candidate differentially edited sites across 135 genes, predominantly enriched in neutrophil-mediated immunity and T-cell differentiation. Transcriptomic analysis revealed distinct stage-associated molecular programs: immunoglobulin production and B-cell receptor signaling were enriched during the acute phase, whereas cell cycle regulation was predominant during remission. CD74 and CDK1 were identified as candidate hub genes in the acute and remission phases, respectively. Furthermore, exploratory analyses suggested nominal associations of acute-phase BCVA with proportions of regulatory T cells and of CD74 expression with estimated neutrophil and monocyte proportions. Discussion: Collectively, these findings characterize RNA-editing alterations and stage-associated immune-transcriptomic features in MOG-ON and provide hypothesis-generating molecular candidates for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.